GRN variant rs5848 reduces plasma and brain levels of granulin in Alzheimer's disease patients

J Alzheimers Dis. 2013;33(1):23-7. doi: 10.3233/JAD-2012-120946.

Abstract

Genetic variants in the granulin (GRN) gene have been shown to increase the risk of Alzheimer's disease (AD). Here, we report that the A allele of rs5848 in GRN reduces plasma granulin levels in a dose-dependent manner in a clinically-defined AD sample cohort. Similarly, the mRNA levels of granulin were decreased with respect to A allele of rs5848 in the inferior temporal cortex of neuropathologically confirmed AD patients. Our findings suggest that the A allele of rs5848 is functionally relevant by reducing the expression of granulin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Alzheimer Disease / blood*
  • Alzheimer Disease / genetics*
  • Alzheimer Disease / metabolism
  • Biomarkers / blood
  • Biomarkers / metabolism
  • Brain / blood supply
  • Brain / metabolism*
  • Brain / pathology*
  • Cohort Studies
  • Down-Regulation / genetics*
  • Female
  • Gene Expression Regulation
  • Genetic Variation / genetics*
  • Humans
  • Intercellular Signaling Peptides and Proteins / biosynthesis
  • Intercellular Signaling Peptides and Proteins / blood*
  • Intercellular Signaling Peptides and Proteins / genetics*
  • Male
  • Middle Aged
  • Oxidation-Reduction
  • Progranulins

Substances

  • Biomarkers
  • GRN protein, human
  • Intercellular Signaling Peptides and Proteins
  • Progranulins